Although not bound to the committee’s recommendations, the FDA does take them into consideration when making decisions on approval. A regulatory decision is expected on December 20, 2024. If approved, ...
Study participants were randomly assigned 2:1 to receive once-weekly subcutaneous semaglutide 2.4mg or placebo alongside standard of care. The primary endpoints for part 1 were resolution of ...
(HealthDay News) — Hormone replacement therapy (HRT) is associated with an increased risk for developing irritable bowel syndrome (IBS) in postmenopausal women, according to a study presented at the ...
The new report, published in the Oct. 31 issue of the US Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, states that the first US case of sexually transmitted TMVII ...
(HealthDay News) — Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, for which costs continue to increase, according to a ...
A health app may be linked to a patient's medical record, but that doesn’t necessarily mean that HIPAA protects the information on that health app.
Guidelines include 52 recommendations on evaluation, pharmacotherapy, invasive interventions, and nonpharmacologic interventions ...
For patients hospitalized with influenza, prevalence of at least one underlying medical condition increased with age.
HealthDay News — Among privately insured patients, there was a doubling in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as antiobesity treatment from 2022 to 2023, with a ...
The hemoglobin elevating agent is being developed for the treatment of anemia associated with multiple diseases.
Subcutaneous semaglutide is currently marketed under the brand name Wegovy for chronic weight management and to reduce the risk of major adverse cardiovascular events in adults with established ...
Individuals who purchased the products should contact their health care providers as abruptly stopping use may result in adverse reactions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback